Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc       US9426831031

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
Actavis plc operates as an investment holding company.It is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand, brand generic, over-the-counter and biosimilar products.The company was founded on October 1, 2013 and is... 
Sector
Pharmaceuticals
Calendar
11/04Earnings Release
Surperformance© rating of Actavis Inc
Trading Rating : Investor Rating :
More about the company
Financials ($)
Sales 2014 12 539 M
EBIT 2014 3 594 M
Net income 2014 1 571 M
Debt 2014 14 870 M
Yield 2014 -
Sales 2015 15 367 M
EBIT 2015 5 300 M
Net income 2015 2 520 M
Debt 2015 10 790 M
Yield 2015 -
PER 2014 41,33
PER 2015 21,04
EV / Sales 2014 6,27x
EV / Sales 2015 4,85x
Capitalization 63 761 M
More Financials
Latest news on ACTAVIS INC
1d ago ACTAVIS : to Host Third Quarter 2014 Earnings Conference Call and Webcast
2d agoDJAllergan Reiterates Opposition to Valeant Bid
6d ago ACTAVIS : Confirms Generic Butrans® Patent Challenge
7d agoDJDOW INDEX OVERSEERS MAKE IT OFFICIAL : U.S. Firms Only
7d ago ACTAVIS IN BUYOUT TALKS WITH SALIX : Cnbc
09/24DJU.S. HOT STOCKS : Hot Stocks to Watch
09/23 Pfizer approaches Actavis to gauge interest in deal - Bloomberg
09/23DJPfizer Has Contacted Actavis About Potential Deal, Parties Not In Formal Talk..
09/16DJU.S. HOT STOCKS : Hot Stocks to Watch
09/09 ACTAVIS : FDA Advisory Committee Recommends Against Approval of Actavis' Nebivol..
09/05 ACTAVIS : Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, ..
09/02 ACTAVIS : Announces FDA Acceptance for Filing of NDA for Eluxadoline
More news
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF